A
Avalo Therapeutics D
D
AVTX
9.500
USD
-0.20
(-2.06%)
مغلق
حجم التداول
471
الربح لكل سهم
-159
العائد الربحي
-
P/E
0
حجم السوق
99,404,514
العنوان: Avalo Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).